Beyond the Petri Dish: Why ATMP Compliance is the New Frontier of Precision Medicine

[中譯] 超越培養皿：為何 ATMP 法規遵循是精準醫療的新疆界

The era of "living drugs"—therapies derived from genes, cells, and tissues—has transitioned from clinical aspiration to a transformative commercial and regulatory reality. Advanced Therapy Medicinal Products (ATMPs) offer the unprecedented potential to repair, replace, or regenerate human biology. However, this innovation exists within a high-stakes legal minefield where the distance between a clinical breakthrough and a total operational shutdown is measured in regulatory precision. A single mislabeled vial or a failure to properly classify a processing step can halt a multi-million dollar operation and jeopardize patient access to life-saving treatment. To navigate this landscape, leaders must bridge the gap between the petri dish and the pillbox, mastering the Good Manufacturing Practice (GMP) requirements that separate successful market entry from catastrophic regulatory failure.
[中譯] 「活體藥物」時代——源自基因、細胞與組織的療法——已從臨床期望轉變為具備變革性的商業與法規現實。先進醫療產品 (ATMPs) 提供了修復、替換或再生人體生物學前所未有的潛力。然而，這項創新存在於一個高風險的法律地雷區中，從臨床突破到全面營運停擺之間的距離，取決於法規的精準度。單一標籤錯誤或未能正確對處理步驟進行分類，即可使數百萬美元的營運停擺，並危及病患獲得救命療法的機會。為了在這領域中航行，領導者必須跨越培養皿與藥盒之間的鴻溝，精通區分成功進入市場與災難性法規失敗的優良製造規範 (GMP) 要求。

Executive Briefing: Strategic Pillars for Leadership

[中譯] 高階主管簡報：領導階層的策略支柱

For executive leadership and clinical directors, ATMP compliance is a strategic imperative that dictates the financial and operational viability of the enterprise. Success in this sector requires a grasp of three core pillars:
[中譯] 對於高階領導團隊與臨床總監而言，ATMP 法規遵循是一項決定企業財務與營運可行性的策略勢要。要在這個領域取得成功，必須掌握三大核心支柱：

• The Risk-Based Approach (RBA): Unlike traditional pharmaceuticals, ATMP regulations allow for flexibility. Manufacturers can design technical and organizational measures tailored to the specific risks of their product, provided these measures are scientifically justified.
  [中譯] 風險導向方法 (RBA)： 與傳統藥品不同，ATMP 法規允許彈性。只要具備科學上的合理性證明，製造商即可針對其產品的特定風險，量身打造技術與組織措施。
• The Necessity of a Pharmaceutical Quality System (PQS): A robust PQS is a non-negotiable requirement. It must ensure that personnel are trained, premises are suitable, and documentation is exhaustive, covering the entire lifecycle from donation to the finished product.
  [中譯] 藥品品質系統 (PQS) 的必要性： 強大的 PQS 是無可妥協的要求。它必須確保人員受過訓練、廠房設施合適，且文件紀錄詳盡，涵蓋從捐贈到成品的整個生命週期。
• The Financial Risk of Misclassification: Misidentifying a product as a medical "technique" rather than a "biological product" triggers immediate enforcement actions, including seizures and injunctions, as oversight from agencies like the FDA intensifies.
  [中譯] 錯誤分類的財務風險： 隨著 FDA 等機構監管力道的加強，將產品錯誤歸類為醫療「技術」而非「生物製劑」，將引發包含扣押與禁制令在內的立即執法行動。

The High Cost of Misclassification: Lessons from Mother Stem

[中譯] 錯誤分類的高昂代價：來自 Mother Stem 的教訓

The regulatory status of a cell-based therapy depends entirely on its processing methods and marketed intent. A recent FDA Warning Letter ( CBER-24-680118) issued to Mother Stem Institute, Corp. serves as a cautionary tale for firms attempting to bypass the biologics licensing process. The firm processed adipose (fat) tissue into stromal vascular fraction (SVF) for intravenous administration, marketing it as an autologous "stem cell" procedure.The FDA’s enforcement hinged on the distinction between minimal and substantial manipulation:
[中譯] 細胞療法的法規狀態完全取決於其處理方法與行銷意圖。近期 FDA 發給 Mother Stem Institute, Corp. 的警告信 ( CBER-24-680118) 成為那些試圖繞過生物製劑授權流程之企業的警示故事。該公司將脂肪組織處理成基質血管細胞群 (SVF) 進行靜脈注射，並將其行銷為自體「幹細胞」程序。FDA 的執法關鍵在於 最小程度 (minimal) 與 實質性 (substantial) 操作的區別：

• Minimal Manipulation: Processing that does not alter the original relevant characteristics of a structural tissue relating to its utility for reconstruction, repair, or replacement.
  [中譯] 最小程度操作： 不改變結構組織原始相關特徵(與其重建、修復或替換之效用有關)的處理程序。
• Substantial Manipulation: Processing—such as the enzymatic digestion used by Mother Stem—that destroys the organized structure of the tissue. Because the SVF was a "heterogeneous collection of cells" that no longer provided the cushioning or support of adipose tissue, it was deemed more than minimally manipulated and regulated as a drug and biological product.
  [中譯] 實質性操作： 諸如 Mother Stem 使用的酵素消化等，破壞了組織有條理的結構的處理程序。由於 SVF 是不再提供脂肪組織緩衝或支撐作用的「異質細胞集合」，因此被認定超越了最小程度操作，並受到藥品與生物製劑的規範。

Simply labeling a product "stem cells" or utilizing a patient's own cells (autologous use) does not exempt a manufacturer from drug regulations. If the process changes the biological nature of the cells or if the product is intended for non-homologous conditions (treating a disease the original tissue did not address), it requires a Biologics License Application (BLA) or an Investigational New Drug (IND) application.
[中譯] 單純將產品標示為「幹細胞」或使用病患的自體細胞 (自體使用)，並不能使製造商豁免於藥品法規的規範。如果處理程序改變了細胞的生物學特性，或者產品意圖用於非同源適應症 (治療原始組織並非用於解決的疾病)，則須提交生物製劑許可申請 (BLA) 或試驗用新藥 (IND) 申請。

"Stem cells obtained from the patient's own fat (autologous) have opened a new door to conquer Alzheimer's disease... Not only does this suppress the death (apoptosis) of neurons in the brain, but it also has a preventative and therapeutic effect against Alzheimer's disease." — FDA Warning Letter CBER-24-680118 (quoting firm's website)
[中譯] 「從病患自體脂肪取得的幹細胞為征服阿茲海默症開啟了一扇新門...這不僅抑制了腦神經細胞的死亡 (細胞凋亡)，也對阿茲海默症具有預防與治療效果。」— FDA 警告信 CBER-24-680118 (引述自該公司網站)

Proportionality and the Risk-Based Approach (RBA)

[中譯] 比例原則與風險導向方法 (RBA)

The European Union’s EudraLex Volume 4, Part IV introduces a philosophy of "proportionality." The RBA recognizes that ATMPs are complex and variable, particularly autologous products where batch sizes are limited to a single patient. This flexibility represents a double-edged sword: while it allows for scientific adaptation, it places the burden of proof entirely on the manufacturer. Every deviation from standard GMP must be documented through a formal Risk Management process, and the manufacturer must provide a scientific justification based on accumulated experience and current scientific knowledge.
[中譯] 歐盟的 EudraLex Volume 4, Part IV 引入了「比例原則」的哲學。RBA 承認 ATMP 是複雜且多變的，特別是批量僅限單一病患的自體細胞產品。這種彈性是一把雙面刃：雖然允許科學適應性，但它將舉證責任完全轉嫁給製造商。每次偏離標準 GMP 規範，都必須透過正式的風險管理流程進行記錄，且製造商必須基於 累積的經驗 與 當前的科學知識 提供科學上的合理性證明。

General Principles of a PQS for ATMPs:
[中譯] ATMP 的 PQS 一般原則：

• Personnel: Adequately trained with a clear allocation of responsibilities.
  [中譯] 人員： 接受充分培訓且職責分配明確。
• Premises and Equipment: Suitable for intended use and rigorously maintained.
  [中譯] 廠房與設備： 適合其預期用途並經過嚴格維護。
• Documentation: An adequate system for specifications of materials, intermediates, and finished products.
  [中譯] 文件紀錄： 具備充分的系統以規範原物料、中間體與成品的規格。
• Manufacturing Process: Designed to ensure consistent production appropriate to the development stage.
  [中譯] 製造流程： 設計以確保生產的一致性，並符合其開發階段。
• Traceability: Robust systems to track the product and its critical raw materials from donor to recipient.
  [中譯] 追溯性： 穩健的系統以追蹤從捐贈者到受贈者的產品及其關鍵原物料。

Navigating the Global Regulatory Maze

[中譯] 穿越全球法規迷宮

Global commercialization requires a nuanced understanding of how different jurisdictions classify and exempt regenerative therapies.
[中譯] 全球商業化需要細緻理解不同司法管轄區如何對再生療法進行分類與豁免。

Region [中譯] 地區	Primary Regulatory Framework [中譯] 主要法規框架	Key Nuance [中譯] 關鍵細節
European Union [中譯] 歐盟	EudraLex Vol 4 Part IV [中譯] EudraLex Vol 4 Part IV	A standalone, ATMP-specific GMP guideline prioritizing the risk-based approach and proportionality. [中譯] 一項獨立的、專為 ATMP 設計的 GMP 指引，優先考慮風險導向方法與比例原則。
Taiwan [中譯] 台灣	Regenerative Medicine Act (2024) [中譯] 再生醫療法 (2024)	Distinguishes between "techniques" and "products." Non-medical institutions are strictly prohibited from implementation. [中譯] 區分「技術」與「產品」。嚴禁非醫療機構執行。
USA [中譯] 美國	FDA Framework (21 CFR 1271) [中譯] FDA 框架 (21 CFR 1271)	Focuses on HCT/P classification; failure to meet "minimal manipulation" or "homologous use" triggers full drug/biologic regulation. [中譯] 專注於 HCT/P 分類；未能符合「最小程度操作」或「同源使用」者，將觸發全面的藥品/生物製劑法規。

In Taiwan, the "Hospital Exemption" (Article 8) allows for the implementation of techniques without full human trials in cases of life-threatening or severely disabling diseases for which no suitable drugs or medical techniques are available in the country. However, these must still meet quality standards equivalent to authorized ATMPs. Crucially, this exemption explicitly excludes the utilization of xenogeneic cells and tissues, a detail vital for clinical directors to monitor.
[中譯] 在台灣，「恩慈療法/醫院免責條款」(第 8 條) 允許在國內缺乏合適藥物或醫療技術的情況下，針對 危及生命或嚴重失能之疾病 執行未經完整人體試驗的技術。然而，這些技術仍須符合與授權 ATMP 相當的品質標準。至關重要的是，此項豁免明確 排除了異種細胞與組織之使用 ，這是臨床總監必須監控的關鍵細節。

Aseptic Rigor and the Realities of Living Therapies

[中譯] 無菌嚴謹度與活體療法的現實

Because living cells cannot undergo terminal sterilization, such as heat or irradiation, without being destroyed, the manufacturing environment is the primary safeguard against contamination. The technical requirements are demanding; for example, in Grade A critical areas, the expected microbial result is 0 cfu recovered. Any recovery of 1 cfu or greater is considered a failure that necessitates an immediate investigation.
[中譯] 由於活細胞無法在不被破壞的情況下進行終端滅菌 (例如高溫或輻射)，製造環境成為防止污染的首要防線。其技術要求極為嚴苛；例如，在 A 級 關鍵區域內，預期的微生物檢測結果為 檢出 0 cfu 。任何 1 cfu 或以上的檢出皆被視為失敗，必須啟動立即調查。

• Environmental Standards: Open systems require a Grade A critical area with a Grade B background. Closed systems (such as isolators) allow for Grade D backgrounds, provided the isolator's integrity is validated.
  [中譯] 環境標準： 開放系統需要 B 級背景下的 A 級關鍵區域。封閉系統 (如隔離衣) 在確認其完整性確效後，允許在 D 級背景下運作。
• Batch Release under Pressure: Many ATMPs have shelf lives measured in hours. EudraLex Part IV allows for "Batch Release" prior to obtaining final 14-day sterility results, provided a robust in-process control strategy is in place. In these scenarios, the treating physician must be informed if full results are not available at the time of release to the clinic.
  [中譯] 高壓下的批次放行： 許多 ATMP 的保存期限僅有數小時。若具備穩健的製程中管制策略，EudraLex Part IV 允許在取得最終 14 天無菌結果前進行「批次放行」。在這些情況下，如果在放行至臨床端時未能取得完整結果， 必須通知主治醫師 。

"It is the responsibility of the ATMP manufacturer to ensure that appropriate measures are put in place to safeguard the quality of the product (so-called 'pharmaceutical quality system')." — EU GMP Guidelines for ATMPs
[中譯] 「ATMP 製造商有責任確保實施適當的措施來維護產品的品質 (即所謂的『藥品品質系統』)。」— 歐盟 ATMP GMP 指引

The 30-Year Digital Thread: Ensuring Lifetime Traceability

[中譯] 30 年數位追溯軌跡：確保生命週期的追溯性

ATMPs require data retention periods that far exceed traditional pharmaceuticals, reflecting the unique long-term risks of genetic and cellular alterations. A bidirectional "thread" must be maintained from the point of donation, through manufacturing, to the recipient. The manufacturer must ensure that the link between internal codes and the Donation Identification Code can always be established.
[中譯] 反映了基因與細胞改變所帶來的獨特長期風險，ATMP 需要遠超傳統藥品的資料保留期限。必須維持從捐贈端、歷經製造、到受贈者的雙向追溯「軌跡」。製造商必須確保能夠隨時建立內部代碼與 捐贈者識別碼 之間的連結。

Data Points Retained for 30 Years:
[中譯] 保留 30 年的資料項目：

• Donation Identification Code: Received from the tissue or blood establishment.
  [中譯] 捐贈者識別碼： 取自組織或血液機構。
• Internal Codes: Generated by the manufacturer to identify tissues/cells throughout processing.
  [中譯] 內部代碼： 由製造商生成，用於在整個處理過程中識別組織/細胞。
• Critical Raw Materials: Identification and batch numbers for all substances contacting cells, including reagents of biological origin and, significantly, scaffolds and matrices.
  [中譯] 關鍵原物料： 所有接觸細胞之物質的標識與批號，包括生物來源試劑，以及特別重要的 支架與基質 。

The storage system must ensure this data is rapidly accessible in the event of an adverse reaction, even decades after administration.
[中譯] 儲存系統必須確保即使在給藥數十年後發生不良反應時，也能迅速存取這些資料。

Harmonization and the Future of SoHO

[中譯] 法規協調與 SoHO 的未來

The regulatory landscape is shifting toward greater integration. The upcoming SoHO (Substances of Human Origin) Regulation (EU) 2024/1938 aims to further harmonize standards for tissues, cells, and blood across the European Union. This transition will require manufacturers to be increasingly agile, particularly regarding cross-border quality systems and the digital tracking of human biological materials.As the industry moves from chemical synthesis to living therapies, the definition of "quality" is evolving from static purity to dynamic biological consistency. Is your quality system agile enough to protect both the patient and the business in this new frontier?
[中譯] 法規環境正朝著更高度的整合轉變。即將生效的 人體來源物質 (SoHO) 規範 (EU) 2024/1938 旨在進一步統一歐盟境內組織、細胞與血液的標準。這項過渡期將要求製造商具備更高的敏捷性，尤其是在跨境品質系統及人體生物材料的數位追蹤方面。隨著產業從化學合成邁向活體療法，「品質」的定義正從靜態的純度演變為動態的生物一致性。在這個新疆界中，您的品質系統是否足夠敏捷，能夠同時保護病患與企業？